Easwaran Ravichandran1,2, Pavithra Janardhanan1, Kruti Patel1, Stephen Riding1, Shuowei Cai1, Bal Ram Singh3,4,5. 1. Department of Chemistry and Biochemistry, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, Massachusetts, 02747, USA. 2. Aurobindo Pharma USA Inc, 6 Wheeling Road, Dayton, New Jersey, 08810, USA. 3. Department of Chemistry and Biochemistry, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, Massachusetts, 02747, USA. bsingh@inads.org. 4. Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, Massachusetts, 02747, USA. bsingh@inads.org. 5. Prime Bio, Inc., Dartmouth, Massachusetts, 02747, USA. bsingh@inads.org.
Abstract
PURPOSE: A double-mutant E224A/E262A full-length botulinum neurotoxin (BoNT) Type A with structural similarity to native BoNT/A but lacking the endopeptidase activity provides an ideal surrogate for testing pharmacokinetics and immunochemical characteristics of BoNT. METHODS: We determined lethality (LD50) of deactivated recombinant botulinum neurotoxin (drBoNT/A) to be 24.0 μg by intraperitoneal route (i.p). The polypeptide drBoNT/A labeled with near infra-red dye 800 (NIR 800) was used to examine its distribution to different organs using whole body imaging when administered to mice via intravenous (i.v) or i.p route. Also, drBoNT/A was used to evaluate its immunogenicity in Balb/C mice model. RESULTS: drBoNT/A was found to be highly immunogenic when tested under various in vivo conditions in Balb/C mice model. For the first time we have demonstrated that a full length 150 kDa drBoNT/A, by administering via inhalation route in mice model, has evoked both circulating immunoglobulin levels of IgG and secretory IgA at the mucosal surface. The immunoglobulin levels were sufficient enough to protect against the challenge dose of native BoNT toxin in mice model. Tissue distribution of drBoNT/A seems to be similar to that of native toxin. CONCLUSIONS: Based on the characteristics described in this report this nontoxic holotoxin protein will assist us to explore the window of opportunity available for therapeutic treatment in case of unnatural poisoning, and also it can be an effective vaccine candidate.
PURPOSE: A double-mutant E224A/E262A full-length botulinum neurotoxin (BoNT) Type A with structural similarity to native BoNT/A but lacking the endopeptidase activity provides an ideal surrogate for testing pharmacokinetics and immunochemical characteristics of BoNT. METHODS: We determined lethality (LD50) of deactivated recombinant botulinum neurotoxin (drBoNT/A) to be 24.0 μg by intraperitoneal route (i.p). The polypeptide drBoNT/A labeled with near infra-red dye 800 (NIR 800) was used to examine its distribution to different organs using whole body imaging when administered to mice via intravenous (i.v) or i.p route. Also, drBoNT/A was used to evaluate its immunogenicity in Balb/C mice model. RESULTS: drBoNT/A was found to be highly immunogenic when tested under various in vivo conditions in Balb/C mice model. For the first time we have demonstrated that a full length 150 kDa drBoNT/A, by administering via inhalation route in mice model, has evoked both circulating immunoglobulin levels of IgG and secretory IgA at the mucosal surface. The immunoglobulin levels were sufficient enough to protect against the challenge dose of native BoNT toxin in mice model. Tissue distribution of drBoNT/A seems to be similar to that of native toxin. CONCLUSIONS: Based on the characteristics described in this report this nontoxic holotoxin protein will assist us to explore the window of opportunity available for therapeutic treatment in case of unnatural poisoning, and also it can be an effective vaccine candidate.
Authors: Robert P Webb; Theresa J Smith; Patrick M Wright; Vicki A Montgomery; Michael M Meagher; Leonard A Smith Journal: Vaccine Date: 2007-03-16 Impact factor: 3.641
Authors: Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson Journal: Infect Immun Date: 2007-03-19 Impact factor: 3.441
Authors: T Söllner; S W Whiteheart; M Brunner; H Erdjument-Bromage; S Geromanos; P Tempst; J E Rothman Journal: Nature Date: 1993-03-25 Impact factor: 49.962
Authors: Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri Journal: Vaccine Date: 2018-01-04 Impact factor: 3.641
Authors: Kruti B Patel; Shuowei Cai; Michael Adler; Brajendra K Singh; Virinder S Parmar; Bal Ram Singh Journal: Appl Environ Microbiol Date: 2018-11-30 Impact factor: 4.792
Authors: Robert P Webb; Theresa J Smith; Leonard A Smith; Patrick M Wright; Rebecca L Guernieri; Jennifer L Brown; Janet C Skerry Journal: Toxins (Basel) Date: 2017-09-03 Impact factor: 4.546